NEW YORK (GenomeWeb) – NanoString Technologies said today that it is collaborating with the NSABP Foundation in a study to characterize immunophenotypes in colorectal cancer.
The partners will use NanoString’s PanCancer IO 360 gene expression panel to test samples from an NSABP biobank of more than 2,500 tumor tissue specimens, looking for targetable pathways such as the microsatellite instability (MSI) phenotype that confers resistance to anti-PD1/PD-L1 therapies.
Overall, NanoString said, the PanCancer IO 360 panel can assay more than 20 signatures associated with therapeutic response to specific agents. In the colorectal cancer collaboration with the NSABP, however, the company will be looking specifically at mismatch repair deficiency and high MSI, and will also be comparing the performance of the PanCancer IO 360 to standard immunohistochemistry testing.
In addition to testing the concordance of the panel with IHC, NanoString and NSABP are also planning to use the assay to investigate new mechanisms of immune evasion in colorectal tumors. For example, the study will focus on NanoString’s Tumor Inflammation Signature (TIS), which researchers described in a paper in the Journal of Clinical Investigation this June. Investigators will test the hypothesis that measuring patients’ TIS could identify a larger population of tumors potentially